Evaluation of mortality attributable to SARS-CoV-2 vaccine administration using national level data from Qatar (2024)

As of June 12, 2022, a total of 6,928,359 SARS-CoV-2 vaccine doses had been administered in Qatar¹¹. Over 99% of the vaccines administered were the mRNA vaccines (BNT-162b2 and mRNA-1273). A total of 4413 deaths were recorded during the study period, with 1726 deaths occurring any time after at least one dose of a SARS-CoV-2 vaccine (162 deaths after 1 dose, 1354 deaths after 2 doses, and 210 deaths after 3 doses) (Fig.1). Fifty-six deaths occurred within 30 days of receiving a first dose (with no second dose administered); 65 within 30 days of the second dose of the vaccine; 17 deaths occurred within 30 days of receiving the third dose of the vaccine (Fig.1).

The median age of final study group (N = 138) was 55 years (IQR 43,70) and the median time from last vaccine to death was 17 days (IQR 11,22). Among them, 113 (81.9%) were male and 31 (22.5%) were Qatari nationals. Among the 138 deaths evaluated, 8 deaths were classified as having high probability of being related to vaccination (1.15 death/1,000,000 vaccine doses administered). Fifteen deaths were classified as having intermediate probability (2.16 death/1,000,000 vaccine doses administered). One hundred and twelve deaths were classified as low probability or not related to vaccination.

Additional analyses

All cases determined to have a high, intermediate, or low probability of association with SARS-CoV-2 vaccination were further individually and separately reviewed by two trained mortality reviewers to assign the most proximal underlying cause(s) that precipitated the terminal event (not “mode of death”, i.e., cardiorespiratory arrest, sepsis without further classification, etc.) according to the World Health Organization criteria for assigning cause of death. Cause of death in all eight cases determined to have high probability of association with vaccination was “sudden cardiac death” in persons with no known risk factors for cardiac disease. Details of the underlying causes and contributory factors are provided in Supplementary Table1.

Since time of death from the time of last vaccination is an arbitrary measure of association, we re-analyzed probability of association using a different time cut-off. Those with no risk factor for mortality were assigned high probability if the death occurred within 15 days, and intermediate probability if death occurred between 16–30 days of vaccine administration. Twenty-nine deaths were thus classified as high probability while 19 deaths were classified as intermediate probability of being related to vaccination.

To our knowledge, this is the first study to report the association between SARS-CoV-2 vaccination and death at a national level. Our results confirm the rarity of association between SARS-CoV-2 vaccination and death.

Crude death rates in Qatar for the years 2019, 2020 and 2021 were 6.60, 7.94, and 8.74 per 100,000 population¹². Death rate among the vaccinated persons with high probability of relationship to SARS-CoV-2 vaccination was 0.34 per 100,000 vaccine recipients, while death rate among the vaccinated persons with either high or intermediate probability of relationship to SARS-CoV-2 vaccination was 0.98 per 100,000 (8 deaths classified as high probability and 15 deaths as intermediate probability among 2,347,635 unique persons who received at least one dose of a vaccine). While these are not age- or sex standardized mortality rates, they offer strong reassurance of extremely low rates of mortality attributable to SARS-CoV-2 vaccination, which is far below the overall crude mortality in the general population. With >90% of Qatar’s population having received at least two doses of the vaccine, the demographics of the vaccinated population are very likely to mirror those of the general population, excluding very young children who were not eligible for vaccination during the study period. There were 435 COVID-19 related deaths during the study period, with 90% occurring among the unvaccinated individuals, suggesting that the benefits of vaccination far outweigh the potential risks. For comparison, an age- and sex-specific breakdown of deaths in Qatar between 2019–2022 is provided in Supplementary Table2.

The strengths of our study include availability of complete national data, a comprehensive review of each death, and use of trained medical personnel who used uniform data instruments to assign the probability of association between SARS-CoV-2 vaccination and death. Each case was reviewed by multiple reviewers to minimize individual bias. The major limitation is the lack of autopsies to determine the exact cause of death. Additionally, the time cut-offs chosen to determine the possible relationship were based on clinical experience and expert opinion of the authors since there are no evidence-based guidance available in this regard.

In conclusion, deaths attributable to SARS-CoV-2 mRNA vaccination are rare and the risk is lower than the overall crude mortality rate in Qatar. These results provide strong assurance regarding the safety of the mRNA vaccines. Our study also provides a strong framework and methodology for future studies to determine associations between vaccination and vaccine related deaths.

Study setting and study population

The study was conducted in the State of Qatar between January 1, 2021 and June 12, 2022. Qatar has a robust, centralized national mortality tracking system to examine all deaths in the country. All deaths in Qatar are individually reviewed by trained licensed physicians dedicated to mortality reviews who extract medical data from the electronic health records and assign direct, antecedent, and contributing causes of death for each case using the World Health Organization recommended definitions¹³. All deaths are processed in the public sector health facilities in Qatar which use an interconnected single electronic health records platform.

For the current study, medical records of all decedents during the study period who received any SARS-CoV-2 vaccine were reviewed. COVID-19 vaccination data for all decedents were retrieved from the Qatar National COVID-19 Database^3,4,5,6. Those who had died within 30 days of receiving a SARS-CoV-2 vaccine dose were eligible for inclusion in the study.

Vaccination and COVID-19 testing data

This study was conducted in the resident population of Qatar. COVID-19 laboratory testing, vaccination, and clinical infection data were extracted from the integrated, nationwide, digital-health information platform that hosts the national, federated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) databases. These databases are complete with no missing information for polymerase chain reaction testing, COVID-19 vaccinations, COVID-19 hospitalizations, and basic demographic details, and have captured all SARS-CoV-2-related data since epidemic onset. Nearly all individuals were vaccinated in Qatar, through the universal public healthcare system for all nationals and residents of Qatar. For rare individuals who received COVID-19 vaccination outside Qatar, vaccination details were recorded in the health system at the port of entry upon return to Qatar, in order to fulfill national requirements and to benefit from privileges associated with vaccination, such as quarantine exemption^{5,14,15,16,17,18}.

Ascertainment of probability of death related to vaccination

We developed an algorithm to determine the probability of a death being related to COVID-19 vaccine administration using a framework similar to the one proposed by the World Health Organization, which takes into account evidence of any other cause of death, temporal association with vaccination, and lack of any other possible explanation^19,20 (Fig.2). Four licensed physicians were trained on the algorithm criteria to independently assign the probability of a death being related to vaccine administration. Final categorization was based on at least three reviewers assigning the same level of probability. Where less than three reviewers assigned the same probability of association, one additional reviewer adjudicated the outcome.

We created four categories of probability of association with SARS-CoV-2 vaccination: Not Related; Low Probability; Intermediate Probability; and High Probability. Cases with more than 2 levels of probability assigned by the four primary reviewers were classified as indeterminate. If a clear alternate and completely unrelated cause of death was identified (e.g., road traffic accident, suicide/homicide, widely metastatic cancer under palliative care), the death was classified as being not related to the vaccination. Presence of one or more severe underlying conditions associated with high risk of mortality (e.g., chronic advanced heart failure, pre-existing atherosclerotic heart disease with prior major adverse cardiovascular events) and physician documentation in the medical records of those contributing directly to death were used to assign low probability, while presence of one or more stable underlying conditions with low risk of short-term mortality and study reviewers’ confirmation of no clear alternate cause of death were used to assign intermediate probability of relationship to vaccination. Those with no underlying conditions and no plausible risk factor for death noted in the medical records or identified by reviewers were further subclassified based on time of death from last SARS-CoV-2 vaccination. Deaths occurring within 5 days of vaccination were classified as having high probability, deaths between 6–15 days as intermediate probability, and deaths occurring 16–30 days as having low probability of being causally associated with vaccination (Fig.2).

All cases determined to have high or intermediate probability of association with SARS-CoV-2 vaccination were further reviewed to ascertain the underlying and contributory cause(s) of death by two trained mortality reviewers using the World Health Organization classification system. This review was specifically intended to identify the cause(s) that directly led to the precipitation of the terminal event that resulted in death.

Data were collected and analyzed in Microsoft Excel for Microsoft 365, Microsoft Corporation, Redmond, WA, USA.

Ethical considerations

The study was approved by the Institutional Review Board at Hamad Medical Corporation. A waiver of informed consent was granted for the study since only decedents records were reviewed and all identifiers were subsequently removed.

Reporting summary

Further information on research design is available in theNature Portfolio Reporting Summary linked to this article.

Authors and Affiliations

1. Corporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar

   Adeel A. Butt,Mylai D. Guerrero,Elenor B. Canlas,Husni Al-Dwairi,Ali Ahmed Sheikh Saleh Alkeldi,Mohammad Fawaz Saber Mohammad,Anil G. Thomas&Abdul-Badi Abou-Samra

2. Department of Medicine, Weill Cornell Medicine, New York, NY, USA

   Adeel A. Butt

3. Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA

   Adeel A. Butt

4. Department of Medicine, Weill Cornell Medicine, Doha, Qatar

   Adeel A. Butt&Abdul-Badi Abou-Samra

5. Department of Population Health Sciences, Weill Cornell Medicine, Doha, Qatar

   Adeel A. Butt

6. Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar

   Abeir Bakhiet Mohammed Ali Alimam,Abdur Rehman Mohamad,Abdullatif Al-Khal&Muna Al-Maslamani

7. Heart Hospital, Hamad Medical Corporation, Doha, Qatar

   Mohammed Thamer Ali&Nidal Ahmad Asaad

   See Also

   14.9 million excess deaths associated with the COVID-19 pandemic in 2020 and 2021

Contributions

Concept and study design: A.A.B. Drafting of the manuscript: A.A.B. Data acquisition: M.D.G., E.B.C., H.A., A.A.S.S.A., and M.F.S.M. Data analysis and interpretation: A.A.B. Critical appraisal and review: A.A.B., M.D.G., E.B.C., H.A., A.B.M.A., A.R.M., M.T.A., N.A.A., A.A.S.S.A., M.F.S.M., A.G.T., A.A., M.A., and A.B.A.S. Final approval of the article: A.A.B., M.D.G., E.B.C., H.A., A.B.M.A., A.R.M., M.T.A., N.A.A., A.A.S.S.A., M.F.S.M., A.G.T., A.A., M.A., and A.B.A.S.

Corresponding author

Correspondence to Adeel A. Butt.

Competing interests

A.A.B. has received investigator initiated grant funding from Gilead Sciences and Merck and Company (to the institution, Veterans Health Foundation of Pittsburgh) which is unrelated to the work presented here. Other authors declare no conflict of interest regarding the content of this article.

Peer review information

Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions